SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is facing downward pressure, with community members debating whether it's losing ground to gold as a safe haven asset. Speculation is swirling around a potential announcement and its possible impact, while others point to technical charts suggesting further declines. Community members are also discussing the potential impact of macro events on Bitcoin's price.

SPDR Gold Trust - SPDR Gold Shares ETF

SPDR Gold Shares ETF

SPDR Gold Shares ETF ($GLD) is trending as gold prices reach new highs, driven by trade tensions and expectations of future rate cuts. The community is actively discussing whether this rally is sustainable or if a significant correction is on the horizon, with some seeing bubble-like conditions. Some traders point to potential factors that could either continue to fuel the run or trigger a pullback.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending as investors discuss the potential impact of China's tightening battery export rules, which could favor the company's U.S.-based solid-state technology; the community is actively debating the stock's recent price action, with some seeing it as a buying opportunity while others express concerns about a possible pullback, also earnings are upcoming with investors hoping to see revenue.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending as traders assess potential downside risk amid geopolitical tensions and anticipation of an upcoming announcement. Community members are weighing the possibility of a sharp reversal against concerns of deeper losses, with focus on key support levels. Discussions also involve broader market factors like bank performance and potential impacts from a former president's comments.

Aptera Motors Corp - Ordinary Shares - Class B

Aptera Motors Corp

Aptera Motors ($SEV) is trending due to its volatile Nasdaq debut, marked by multiple trading halts and a wide price range. The community is actively discussing entry points, potential shorting activity, and the company's long-term prospects in the solar EV market. Despite the initial turbulence, some investors remain optimistic about Aptera's technology and future potential.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending as traders hedge against market uncertainty, with community members discussing potential upside driven by geopolitical tensions and economic data. Some are debating whether the recent moves signal a larger correction, while others are looking to profit from short-term volatility. The fund's movements are being closely watched amid broader concerns about market valuations and the potential impact of a government shutdown.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as the community debates the stock's valuation and potential catalysts, including Trump's involvement and the company's Bitcoin holdings. Discussions also involve the broader implications of tariffs and government spending. Concerns about dilution and the company's financial performance are prominent talking points.

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Praxis Precision Medicines Inc

PRAX is trending as traders discuss its recent surge following positive Phase 3 trial results for its essential tremor treatment, with analysts issuing bullish price targets. Community chatter revolves around short squeezes, potential profit-taking, and whether the company will pursue a dilutive offering. The stock is also being mentioned in the context of other bio stocks experiencing similar momentum.

Kenvue, Inc. is a consumer health company, which engages in manufacturing and selling healthcare products which includes cosmetics, drugs, and medical devices. Its brands include Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol. It operates through the following segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care, and others. The Essential Health segment focuses on oral care, baby care, women's health, and wound care. The company was founded on February 23, 2022 and is headquartered in Summit, NJ.

Kenvue Inc

Kenvue is trending due to legal challenges in the UK concerning talc-related cancer claims, sparking a sell-off despite the company's denial of the allegations. Community discussions revolve around the potential liability for Kenvue versus J&J, the extent of the overreaction, and whether this presents a buying opportunity given the company's dividend and well-known brands. Some traders are looking at short-term call options, while others are considering longer-term positions based on value and potential bounce-back.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Johnson & Johnson is trending amid developments in the legal landscape, including a lawsuit in the UK concerning talc-related cancer claims linked to Kenvue, its former consumer health unit. Simultaneously, investors are monitoring J&J's strategic shift, particularly its plan to spin off its Orthopaedics unit to sharpen its MedTech focus, while the community debates its potential impact and strategic rationale.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are Medical Stocks Lagging  Aquestive Therapeutics (AQST) This Year?

Here is how Aquestive Therapeutics (AQST) and Arcturus Therapeutics (ARCT) have performed compared to their sector so far this year.

Aquestive Therapeutics (AQST) Surges 7.9%: Is This an Indication of Further Gains?

Aquestive Therapeutics (AQST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Shares of Aquestive Therapeutics jumped more than 11% in after-hours trading Thursday after CEO Dan Barber said the company’s oral epinephrine film, Anaphylm, could become a “blockbuster” drug with as much as $1 billion in peak global sales.Barber&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/video/2025/09/25/aquestive-ceo-on-its-potential-1-billion-blockbuster-product.html">said in an interview</a> on CNBC’s "Mad Money" with Jim Cramer, noting that despite winning six FDA approvals and distributing 2.5 billion doses worldwide over the past two decades, Aquestive has historically remained small, with annual revenue of $50 million to $70 million.&nbsp;He said Anaphylm, designed to treat severe allergic reactions with a dissolvable sublingual film instead of an auto-injector, represents the company’s first chance at a broad-market product.Cramer, who first highlighted the stock earlier this month as a speculative pick, pointed to Anaphylm’s potential as an alternative to epinephrine auto-injectors like the EpiPen.Earlier this month, Aquestive said that the FDA has determined an advisory committee meeting is not required for Anaphylm, maintaining the Prescription Drug User Fee Act target action date of January 31, 2026.&nbsp;Oppenheimer raised its price target on Aquestive to $8 from $7 following the announcement, reiterating its ‘Outperform’ rating and noting that investors interpret the FDA decision as increasing the chances of approval.The company has also outlined its regulatory strategy outside the U.S., saying in July that Health Canada granted a meeting to discuss its planned New Drug Submission for Anaphylm and that an initial briefing package has been submitted to the European Medicines Agency.&nbsp;Aquestive said Canada and Europe represent “ideal initial international markets” for the drug, given regulatory alignment and patient need.To prepare for a potential launch, Aquestive has raised about $160 million in financing, which Barber said positions the company to ensure broad outreach to providers, caregivers, and patients once the FDA decision is made.On Stocktwits, retail sentiment for Aquestive was ‘bullish’ amid ‘high’ message volume.One user said that Barber’s appearance on&nbsp;CNBC’s “Mad Money” show&nbsp;was a turning point for Aquestive Therapeutics, saying the CEO “really painted the company in a great light” by backing up Anaphylm’s projected value with current epinephrine market data.&nbsp;<stembedurl>https://stocktwits.com/YaBoyJ313/message/630079945</stembedurl>Another user suggested that Aquestive could become a buyout target within two years of Anaphylm sales, predicting the stock could climb from about $10 to $25 if that scenario&nbsp;were to play out.<stembedurl>https://stocktwits.com/ImPoorAndHungry/message/630067707</stembedurl><a href="https://stocktwits.com/symbol/AQST">Aquestive’s stock</a> has risen 47.8% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Aquestive’s stock (AQST) has risen 47.8% so far in 2025. (Photo credit: Getty Images)

Aquestive Stock Jumps After-Hours As CEO Sees $1B ‘Blockbuster’ Potential For Oral Allergy Film — Retail Sees Stock As Buyout Candidate

Aquestive’s Anaphylm has drawn heightened investor attention after the CEO spotlighted it as the company’s first broad-market product.

Why Aquestive Therapeutics Stock Jumped After-Hours Today

Equity

Aquestive Therapeutics (AQST) Soars 14.8%: Is Further Upside Left in the Stock?

Aquestive Therapeutics (AQST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA

Aquestive Therapeutics shares surge after FDA skips advisory meeting on Anaphylm NDA, keeping its January 2026 action date intact.

Aquestive Therapeutics (AQST) on Thursday said that the U.S. Food and Drug Administration has informed the Company that an advisory committee meeting is not required for Anaphylm Sublingual Film.Anaphylm Sublingual Film is a polymer matrix-based epinephrine prodrug product candidate. It is similar in size to a postage stamp and begins to dissolve on contact. No water or swallowing is required for administration.According to Aquestive, Anaphylm has the potential to be the first and only orally delivered epinephrine product for the treatment of severe allergic reactions in the U.S., doing away with the need for injections. The FDA is expected to decide on Aquestive’s application for approval of the sublingual film by January 31, 2026.Aquestive CEO Dan Barber <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-fda-will-not-require-advisory">said</a> that the company is encouraged by the FDA’s decision to waive a meeting and added that the company is “well-positioned” for launch. Shares of the company traded 17% higher in the premarket session.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AQST">AQST stock</a> stayed within ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels. A Stocktwits user opined that the stage is now set for approval of Anaphylm.<stembedurl>https://stocktwits.com/BioAmerica/message/627450441</stembedurl>Last month, Aquestive <a href="https://stocktwits.com/news-articles/markets/equity/aquestive-therapeutics-enters-75-million-dollar-funding-agreement/chsRkEVRdOO">said</a> that it entered into a $75 million strategic funding agreement with funds managed by RTW Investments, LP. The financing will become available upon approval of Anaphylm by the FDA and satisfaction of certain refinancing and other customary conditions. Barber said that the financing will support the company through 2027 and allow it to successfully bring Anaphylm to market.RTW, meanwhile, will receive a tiered single-digit percentage of annual net sales of Anaphylm in the U.S. for the treatment of type I allergic reactions, including anaphylaxis, subject to a cap.AQST stock is up by 11% this year but down by about 7% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/ethereum-outperforms-bitcoin-while-broader-crypto-market-slips/chwd22IRdYJ">Ethereum Outperforms Bitcoin, While Broader Crypto Market Slips</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

FDA Says No Advisory Committee Meeting Needed For Aquestive’s Oral Epinephrine Film

 The FDA is expected to decide on Aquestive’s application for approval of the sublingual film by January 31, 2026. 

Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?

Here is how Aquestive Therapeutics (AQST) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.

Aquestive Therapeutics, Inc. (AQST) on Thursday said that it has entered into a $75 million strategic funding agreement with funds managed by RTW Investments, LP, subject to U.S. Food and Drug Administration (FDA) approval of Anaphylm Sublingual Film.The financing will become available upon approval of Anaphylm by the FDA and satisfaction of certain refinancing and other customary conditions. Aquestive CEO Dan Barber <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/08/14/3133251/0/en/Aquestive-Therapeutics-Announces-75M-Strategic-Funding-Agreement-with-RTW-to-Support-the-Potential-Launch-of-Anaphylm-epinephrine-Sublingual-Film.html">said</a> that the financing will support the company through 2027 and allow it to successfully bring Anaphylm to market.Under the terms of the agreement, RTW will receive a tiered single-digit percentage of annual net sales of Anaphylm in the U.S. for the treatment of type I allergic reactions, including anaphylaxis, subject to a cap.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AQST">AQST</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels. Shares of the company traded 6% higher in the pre-market session.<figure class="image"><img style="aspect-ratio:631/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_14_at_7_57_19_AM_png_2d91151e35.webp" alt="AQST's Sentiment Meter and Message Volume as of 8:07 a.m. ET on Aug. 14, 2025 | Source: Stocktwits" width="631" height="62"><figcaption>AQST's Sentiment Meter and Message Volume as of 8:07 a.m. ET on Aug. 14, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user believes uncertainty about funding is out of the way.<stembedurl>https://stocktwits.com/SonOfLionel19/message/625113435</stembedurl>Another, however, opined that the company would need more funds to launch the drug.<stembedurl>https://stocktwits.com/ae1213/message/625112218</stembedurl>Anaphylm Sublingual Film is a polymer matrix-based epinephrine prodrug product candidate. It is similar in size to a postage stamp and begins to dissolve on contact. No water or swallowing is required for administration.According to Aquestive, Anaphylm has the potential to be the first and only orally delivered epinephrine product for the treatment of severe allergic reactions in the U.S. The FDA is expected to decide on the candidate by January 31, 2026.Separately, the company also announced pricing of an underwritten offering of 21.25 million shares of its common stock at an offering price of $4.00 per share. The gross proceeds of the offering to Aquestive are expected to be $85 million.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/08/14/3133263/0/en/Aquestive-Therapeutics-Announces-Pricing-of-85-Million-Underwritten-Offering-of-Common-Stock.html">said</a> it intends to use the net proceeds received from the offering primarily to advance the launch and commercialization of Anaphylm.AQST stock is up by 13% this year and by about 4% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-inks-up-to-1.3-billion-deal-with-superluminal-medicines/chsRS3IRdO7">Eli Lilly Inks Up To $1.3B Deal With Superluminal Medicines To Develop Obesity Drugs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Aquestive Therapeutics Stock Is Rising Pre-Market – Its $75M Funding Agreement Draws Divided Opinions From Retail

Aquestive CEO Dan Barber said that the $75 million financing will support the company through 2027 and allow it to successfully bring Anaphylm to market.

Compared to Estimates, Aquestive Therapeutics (AQST) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Aquestive Therapeutics (AQST) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Aquestive Therapeutics (AQST) Reports Q2 Loss, Lags Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of +22.22% and -9.62%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Aquestive Therapeutics Inc

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

AQST
Aquestive Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest AQST News

AQSTAquestive Therapeutics Inc